Autologous Stem Cell And Non-Stem Cell Based Therapies Market By Application (Cancer And Autoimmune Diseases, Cardiovascular Diseases, Infectious Diesease, Neurodegenerative Diseases, Skin Transplantation), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jul 25, 2016

Key Findings


The increasing prevalence of lifestyle oriented diseases across the globe and growing adoption of protein based drugs is driving the growth of the global autologous stem cell and non-stem cell based therapies market. Various health regulatory bodies are expecting that universities and companies to innovate new therapy treatments, which ensures better, affordable, safer, easy to use, effective and rapid therapy treatment to end users. Autologous stem cell transplantation is safer than the other transplantation procedure with minimal steps in procedure that provides rapid results. However, there are various sources of autologous stem cell therapy such as Hematopoietic stem cells;Mesenchymal stem;Chondrocytes; and, many others. Moreover, due to the imposition of government bodies the autologous stem cell therapy is experiencing robust growth in the global market. Furthermore, the growing investment in R&D is injecting positive growth in the market. The overall R&D backing for autologous stem cell therapy research has amplified significantly in the past 5 to 10 years and it is projected to reach desired heights in the coming years. The various venture capital firms are investing huge sum of money in autologous stem cell therapy study. Government funding agencies areon track to recognize the future assistances of autologous stem cell therapymarket. The rising prevalence of neurodegenerative disorders and therise in the medical tourism is creating huge scope of growth for the market. Also, thedevelopment of the contract research industryisexpected to contribute towards the growth of the global autologous stem cell and no-stem cell based therapies market. However, the market is growing by various factors, but,in spite of the presence of several driving factors, there are a few factors such as tools used in autologous stem cell and non-stem cell based therapies; unfavorablegovernment regulations and reimbursement policies; and,the limited number of service providers may hamper the growth of the global market. Whereas, huge growth potential in untapped regions ofAPAC; substituting animal tissue in drug discovery; and, rapid growth of the contract research industry is expected to contribute largely towards the market; and, are the key opportunities present in front of global autologous stem cell and non-stem cell based therapies market. Moreover, stringent and unfavorable government regulations creating burden and lack of awareness among people in the emerging economies are a few challenges that are expected to hamper the growth of the global autologous stem cell and non-stem cell based therapies market.


Market Segment Insight


The global autologous stem cell and non-stem cell based therapies market is segmented into application and geography. The application segment is further sub-divided into cancer and autoimmune diseases; cardiovascular diseases; infectious diseases; neurodegenerative diseases; and, skin transplantation. The rising number of cancer and cardiovascular diseases across the globe is expected to boost the growth in the global market. The cancer and autoimmune diseases holds the largest market share in the application segment. However, the infectious diseases are anticipated to have huge growth opportunity during the forecast period.


Regional Insight


Globally, the autologous stem cell and non-stem cell based therapiesmarket is segmented intoNorth America, Europe, APAC,and ROW. North America region holds the largest market share in the global autologous stem cell and non-stem cell based therapies market, followed by Europe. The large market share of North America region is majorly driven by the high incidences of cancer and cardiovascular diseases; presence of large number of patients requiring transplantation; rising government support and funding;and, rising healthcare expenditure in the North American region. The Asia Pacific market is expected to growth with the impulsive CAGR in the forecast period. The impulsive growth is attributed by increasing population in emerging countries such as China and India due to which the number of patients in the region are increasing rapidly. The mounting incidences of cancer and cardiovascular diseases in the region; presence of large number of patients requiring transplantation; rising government support and funding; and, rise in medical tourism in the region is expected to create huge scope for the growth of the market.The growing patient baseof neurodegenerative diseases and growing development of healthcare infrastructure due to therising demand for quality healthcare in the region is also boosting the regional market. Growing technological advancements are also injecting huge growth opportunities in the Asia Pacific autologous stem cell and non-stem cell based therapies market. The ROW market is expected to see a balanced growth during the forecast period of 2016-2022. The growth in the region is majorly fueled by the pilingnumber of incidences of cancer and cardiovascular diseases in the region, along with rising neurodegenerative diseases are also creating huge scope in the regional autologous stem cell and non-stem cell therapies market.

 

Competitive Insights


Some of the keymarket playersare Antria (Cro); Bioheart; Brainstorm Cell Therapeutics; Dendreon Corporation; Genesis Biopharma; Georgia Health Sciences University; Orgenesis; Regenexx; and, Tengion.Acquisitions, mergers, product development, joint ventures and expansions are the key strategies adopted by the market players to sustain in the market.

CHAP 1. METHODOLOGY & SCOPE 11
1.1. RESEARCH METHODOLOGY 11
1.2. RESEARCH SCOPE & ASSUMPTIONS 11
1.3. LIST OF DATA SOURCES 11


CHAP 2. EXECUTIVE SUMMARY 12
2.1. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET SUMMARY & KEY BUYING CRITERIA 12
2.2. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET OUTLOOK 12
2.3. MARKET SEGMENTATION ANALYSIS 12
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 12
2.5. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET VALUE CHAIN ANALYSIS 12
2.6. VENDOR LANDSCAPE 12


CHAP 3. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET 13
3.1. MARKET DRIVER ANALYSIS 13
3.1.1. GROWING PREVALENCE OF CANCER AND CARDIOVASCULAR DISEASES 13
3.1.2. LARGE NUMBER OF PATIENTS REQUIRING TRANSPLANTATION 13
3.1.3. RISING GOVERNMENT SUPPORT AND FUNDING 13
3.1.4. RISE IN MEDICAL TOURISM CREATING HUGE SCOPE 13
3.1.5. INCREASING STEM CELL BANKING 13
3.1.6. INCREASING INVESTMENTS IN R&D 13
3.1.7. TECHNOLOGICAL ADVANCEMENT ENABLING RAPID GROWTH 13
3.1.8. RISE IN NEURODEGENERATIVE DISEASES CREATING SCOPE 13
3.2. MARKET RESTRAINT ANALYSIS 13
3.2.1. LACK OF SERVICE PROVIDERS 13
3.2.2. UNFAVORABLE REIMBURSEMENT POLICIES 13
3.3. KEY OPPORTUNITIES 13
3.3.1. HUGE SCOPE OF GROWTH IN UNTAPPED APAC REGION 13
3.3.2. SUBSTITUTING ANIMAL TISSUE IN DRUG DISCOVERY 13
3.3.3. INCREASING DISPOSABLE INCOME ACROSS GEOGRAPHIES 13
3.3.4. CONTRACT RESEARCH INDUSTRY EXPECTED TO CONTRIBUTE 13
3.4. CHALLENGES 13
3.4.1. STRINGENT GOVERNMENT REGULATIONS 13
3.4.2. LACK OF AWARENESS IN EMERGING ECONOMIES 13


CHAP 4. INDUSTRY ANALYSIS 14
4.1. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET– PORTER’S FIVE FORCE MODEL 14
4.2. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET– PESTEL ANALYSIS 14
4.3. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET– GAP ANALYSIS 14


CHAP 5. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION 2012-2022 ($ MILLION) 15
5.1. GLOBAL CANCER AND AUTOIMMUNE DISEASES MARKET 2012-2022 ($ MILLION) 15
5.2. GLOBAL CARDIOVASCULAR DISEASES MARKET 2012-2022 ($ MILLION) 15
5.3. GLOBAL INFECTIOUS DIESEASE MARKET 2012-2022 ($ MILLION) 15
5.4. GLOBAL NEURODEGENERATIVE DISEASES MARKET 2012-2022 ($ MILLION) 15
5.5. GLOBAL SKIN TRANSPLANTATION MARKET 2012-2022 ($ MILLION) 15


CHAP 6. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 16
6.1. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY REGION 2012-2022 ($ MILLION) 16
6.2. NORTH AMERICA 16
6.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 16
6.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 16
6.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 16
6.2.3.1. U.S. 16
6.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 16
6.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 16
6.2.3.2. CANADA 16
6.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 16
6.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 16
6.3. EUROPE 16
6.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 16
6.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 16
6.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 16
6.3.3.1. GERMANY 16
6.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 17
6.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 17
6.3.3.2. UK 17
6.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 17
6.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 17
6.3.3.3. FRANCE 17
6.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 17
6.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 17
6.3.3.4. RUSSIA 17
6.3.3.4.1. RUSSIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 17
6.3.3.4.2. RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 17
6.3.3.5. REST OF EUROPE 17
6.3.3.5.1. ROE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
6.3.3.5.2. ROE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
6.4. ASIA PACIFIC 18
6.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
6.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
6.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
6.4.3.1. CHINA 18
6.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
6.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
6.4.3.2. INDIA 18
6.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
6.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
6.4.3.3. JAPAN 18
6.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
6.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
6.4.3.4. ROAPAC 18
6.4.3.4.1. ROAPAC MARKET ESTIMATES AND FORECASTS 2012-2022 ($ MILLION) 19
6.4.3.4.2. ROAPAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
6.5. REST OF THE WORLD 19
6.5.1. REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
6.5.2. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
6.5.3. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 19
6.5.3.1. LATIN AMERICA 19
6.5.3.1.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
6.5.3.1.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
6.5.3.2. MIDDLE EAST AND AFRICA 19
6.5.3.2.1. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
6.5.3.2.2. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19


CHAP 7. COMPETITIVE LANDSCAPE 20
7.1. ANTRIA (CRO) 21
7.1.1. COMPANY OVERVIEW 21
7.1.2. SCOT ANALYSIS 21
7.1.3. PRODUCT BENCHMARKING 21
7.1.4. STRATEGIC INITIATIVES 21
7.2. BIOHEART 21
7.2.1. COMPANY OVERVIEW 21
7.2.2. SCOT ANALYSIS 21
7.2.3. PRODUCT BENCHMARKING 21
7.2.4. STRATEGIC INITIATIVES 21
7.3. BRAINSTORM CELL THERAPEUTICS 21
7.3.1. COMPANY OVERVIEW 21
7.3.2. SCOT ANALYSIS 21
7.3.3. PRODUCT BENCHMARKING 21
7.3.4. STRATEGIC INITIATIVES 21
7.4. CYTORI 21
7.4.1. COMPANY OVERVIEW 21
7.4.2. SCOT ANALYSIS 21
7.4.3. PRODUCT BENCHMARKING 21
7.4.4. STRATEGIC INITIATIVES 21
7.5. DENDREON CORPORATION 21
7.5.1. COMPANY OVERVIEW 21
7.5.2. SCOT ANALYSIS 21
7.5.3. PRODUCT BENCHMARKING 21
7.5.4. STRATEGIC INITIATIVES 21
7.6. FIBROCELL 21
7.6.1. COMPANY OVERVIEW 21
7.6.2. SCOT ANALYSIS 22
7.6.3. PRODUCT BENCHMARKING 22
7.6.4. STRATEGIC INITIATIVES 22
7.7. GENESIS BIOPHARMA 22
7.7.1. COMPANY OVERVIEW 22
7.7.2. SCOT ANALYSIS 22
7.7.3. PRODUCT BENCHMARKING 22
7.7.4. STRATEGIC INITIATIVES 22
7.8. GEORGIA HEALTH SCIENCES UNIVERSITY 22
7.8.1. COMPANY OVERVIEW 22
7.8.2. SCOT ANALYSIS 22
7.8.3. PRODUCT BENCHMARKING 22
7.8.4. STRATEGIC INITIATIVES 22
7.9. NEOSTEM 22
7.9.1. COMPANY OVERVIEW 22
7.9.2. SCOT ANALYSIS 22
7.9.3. PRODUCT BENCHMARKING 22
7.9.4. STRATEGIC INITIATIVES 22
7.10. OPEXA THERAPEUTICS 22
7.10.1. COMPANY OVERVIEW 22
7.10.2. SCOT ANALYSIS 22
7.10.3. PRODUCT BENCHMARKING 22
7.10.4. STRATEGIC INITIATIVES 22
7.11. ORGENESIS 22
7.11.1. COMPANY OVERVIEW 22
7.11.2. SCOT ANALYSIS 22
7.11.3. PRODUCT BENCHMARKING 22
7.11.4. STRATEGIC INITIATIVES 22
7.12. REGENEXX 23
7.12.1. COMPANY OVERVIEW 23
7.12.2. SCOT ANALYSIS 23
7.12.3. PRODUCT BENCHMARKING 23
7.12.4. STRATEGIC INITIATIVES 23
7.13. REGENEUS 23
7.13.1. COMPANY OVERVIEW 23
7.13.2. SCOT ANALYSIS 23
7.13.3. PRODUCT BENCHMARKING 23
7.13.4. STRATEGIC INITIATIVES 23
7.14. TENGION 23
7.14.1. COMPANY OVERVIEW 23
7.14.2. SCOT ANALYSIS 23
7.14.3. PRODUCT BENCHMARKING 23
7.14.4. STRATEGIC INITIATIVES 23
7.15. VIRXSYS 23
7.15.1. COMPANY OVERVIEW 23
7.15.2. SCOT ANALYSIS 23
7.15.3. PRODUCT BENCHMARKING 23
7.15.4. STRATEGIC INITIATIVES 23

TABLE 1 GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION 2012-2022 ($ MILLION) 23
TABLE 2 GLOBAL CANCER AND AUTOIMMUNE DISEASES MARKET 2012-2022 ($ MILLION) 23
TABLE 3 GLOBAL CARDIOVASCULAR DISEASES MARKET 2012-2022 ($ MILLION) 23
TABLE 4 GLOBAL INFECTIOUS DIESEASE MARKET 2012-2022 ($ MILLION) 24
TABLE 5 GLOBAL NEURODEGENERATIVE DISEASES MARKET 2012-2022 ($ MILLION) 24
TABLE 6 GLOBAL SKIN TRANSPLANTATION MARKET 2012-2022 ($ MILLION) 24
TABLE 7 NORTH AMERICA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 24
TABLE 8 NORTH AMERICA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 24
TABLE 9 NORTH AMERICA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 24
TABLE 10 U.S. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 24
TABLE 11 U.S. GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 24
TABLE 12 CANADA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 24
TABLE 13 CANADA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 24
TABLE 14 CANADA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 24
TABLE 15 EUROPE GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 24
TABLE 16 EUROPE GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY REGION 2012–2022 ($ MILLION) 24
TABLE 17 EUROPE GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 25
TABLE 18 GERMANY GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 25
TABLE 19 GERMANY METABOLOMICS TECHNOLOGY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 25
TABLE 20 UK GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 25
TABLE 21 UK GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 25
TABLE 22 ASIA PACIFIC GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 25
TABLE 23 ASIA PACIFIC GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY REGION 2012–2022 ($ MILLION) 25
TABLE 24 ASIA PACIFIC GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 25
TABLE 25 CHINA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 25
TABLE 26 CHINA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 25
TABLE 27 INDIA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 25
TABLE 28 INDIA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 25
TABLE 29 JAPAN GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 26
TABLE 30 JAPAN GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 26
TABLE 31 MIDDLE EAST & AFRICA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012–2022 ($ MILLION) 26
TABLE 32 MIDDLE EAST & AFRICA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 26
TABLE 33 LATIN AMERICA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 26
TABLE 34 LATIN AMERICA GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET ESTIMATES AND FORECAST BY APPLICATION 2012–2022 ($ MILLION) 26

FIGURE 1 MARKET SHARE BY REGIONS 26
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
FIGURE 9 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
FIGURE 10 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
FIGURE 11 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
FIGURE 12 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
FIGURE 13 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
FIGURE 14 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)